#记录我的2024#在中国医疗资本市场上, Robust Medical is undoubtedly a very famous company, a few years ago, when the mask was on fire, Robust Medical made great progress, but the recent financial report of Robust Medical showed that net profit fell by 6%, which makes people want to ask where should Robust Medical go in the post-mask era?
1. The net profit of Robust Medical has dropped by more than 60%?
According to a report by Jiemian News, Robust Medical released its 2023 annual report. According to the annual report, in 2023, Wenwen Medical will achieve revenue of 8.185 billion yuan, a year-on-year decrease of 27.89%, a net profit of 580 million yuan, a year-on-year decrease of 64.84%, and a non-net profit of 412 million yuan, a year-on-year decrease of 73.61%. In addition, the net cash flow generated by Wenwen Medical's operating activities was 1.063 billion yuan, a year-on-year decrease of 64.36%.
The main business of Win Medical can be divided into two sectors, one is the medical consumables sector with the "Winner Stable Medical" brand as the core, and the other is the consumer sector with the "Purcotton Cotton Times" brand.
The product categories of Robust Medical Medical Consumables segment are divided into traditional wound care and dressing, high-end wound dressings, operating room consumables, infection protection, health and personal care, and other products.
In the past three years, infection prevention products have been the majority of Robust Medical's revenue and net profit. In 2022, robust medical infection protection products contributed 4.735 billion yuan, accounting for 41.72% of total revenue.
By 2023, infection protection products will contribute only 912 million yuan in revenue, accounting for 11.15% of total revenue. The market demand for infection protection products has decreased significantly since the second quarter, and the annual operating income of this category has decreased by 3.82 billion yuan year-on-year, a year-on-year decrease of 80.7%, under the high market inventory.
At the end of 2022, the production volume of robust medical infection protection products has experienced a round of sudden increase, which has generated greater pressure to destock. According to the annual report, in 2022, Robust Medical will produce a total of 6.06 billion masks, a year-on-year increase of 64.52%, and 49.7597 million pieces of protective clothing, a year-on-year increase of 234.93%.
2. Where should robust medical care go in the post-mask era?
Recently, the financial report released by Robust Medical showed that the company's net profit fell sharply, a decline of more than 60%. This news has aroused widespread concern in the market about the future development of Robust Medical. In the post-mask era, what are the challenges facing Robust Medical, how to find new growth points, and how should we look at this matter?
First of all, considering the overcapacity of Robust Medical in the past two years, the decline in net profit is to be expected. The special situation in previous years has given rise to the production of a large number of masks and protective equipment, and the inventory digestion of these products has become a major pressure for the company. The surge in demand for these products has led companies such as Robrobin Medical to quickly expand production capacity to meet short-term demand. However, when the market is fully opened up and market demand returns to normal levels, excess inventory becomes a heavy burden. In this case, the company had to take measures such as price reductions and promotions to reduce inventory, which affected profit margins.
Secondly, although Wenwen Medical is facing the dilemma of a sharp decline in net profit, its medical consumables business still maintains a steady development trend. After excluding infection protection products, Robin Medical's conventional medical consumables business achieved double-digit growth, demonstrating the company's market competitiveness in this field. However, the development of the medical consumables business also faces some challenges. On the one hand, with the continuous progress of medical technology and the intensification of market competition, customers have higher and higher requirements for the quality and performance of medical consumables. Robust Healthcare requires continuous investment in R&D and innovation to meet the needs of its customers and maintain a competitive edge. On the other hand, the regulatory policies of the medical consumables market are also constantly changing, and companies need to pay close attention to policy developments to ensure compliance operations.
Third, the all-cotton era, a consumer brand under Robust Medical, has also shown certain development bottlenecks. As a brand with the concept of high quality and health as the core, the cotton era has also attracted attention in previous years, but with the decline of consumer purchasing power and the intensification of market competition, the sales of its core products may have reached the ceiling, and the growth rate has begun to slow down. At the same time, the lack of new explosive products to fill the growth gap is also a problem currently faced. Against this backdrop, companies need to innovate and launch new products that meet market needs in order to maintain their attractiveness in the consumer market.
Fourth, in the post-mask era, the core problem to be solved by Robust Medical is to find new growth points. This is not only innovation at the product level, but also the consideration of the entire business model and strategic positioning. On the one hand, the company can use the existing brand influence and technology accumulation, strengthen cooperation with other medical institutions, and deepen the R&D and market layout in the field of medical consumables; on the other hand, for the consumer market, Robust Medical needs to gain insight into market trends and develop new consumer needs, such as personalized and intelligent medical products, so as to drive new consumption hotspots.
Therefore, after experiencing the challenge of a sharp decline in net profit, Robust Medical needs to start from multiple dimensions, not only to deepen the layout in the field of medical consumables, but also to seek innovative breakthroughs in the consumer market, only in this way can it truly form its own long-term competitiveness.